Financial Review: Dyadic International (OTCMKTS:DYAI) & Its Peers
Dyadic International (OTCMKTS: DYAI) is one of 32 public companies in the “Commercial physical research” industry, but how does it contrast to its peers? We will compare Dyadic International to related businesses based on the strength of its institutional ownership, valuation, earnings, risk, profitability, dividends and analyst recommendations.
This table compares Dyadic International and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Dyadic International Competitors||-303.61%||-211.37%||-45.39%|
0.0% of Dyadic International shares are held by institutional investors. Comparatively, 46.0% of shares of all “Commercial physical research” companies are held by institutional investors. 16.1% of shares of all “Commercial physical research” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This is a summary of current ratings and price targets for Dyadic International and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Dyadic International Competitors||126||600||1377||57||2.63|
As a group, “Commercial physical research” companies have a potential upside of 19.06%. Given Dyadic International’s peers higher possible upside, analysts clearly believe Dyadic International has less favorable growth aspects than its peers.
Risk and Volatility
Dyadic International has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500. Comparatively, Dyadic International’s peers have a beta of 4.28, suggesting that their average share price is 328% more volatile than the S&P 500.
Valuation & Earnings
This table compares Dyadic International and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Dyadic International||$760,000.00||-$2.14 million||-11.06|
|Dyadic International Competitors||$968.26 million||$63.67 million||12.47|
Dyadic International’s peers have higher revenue and earnings than Dyadic International. Dyadic International is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Dyadic International peers beat Dyadic International on 8 of the 10 factors compared.
About Dyadic International
Dyadic International, Inc., a biotechnology company, engages in the discovery, development, production, and sale of enzymes and other proteins in the United States and the Netherlands. It utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial production of human and animal vaccines, monoclonal antibodies, biosimilars and/or biobetters, and other therapeutic proteins. Dyadic International, Inc. has a research collaboration with Mitsubishi Tanabe Pharma Corporation to explore the potential of its C1 technology to produce two vital therapeutic proteins for human health indications; and the Sanofi-Aventis Deutschland GmbH to explore the potential of its C1 technology to produce various types of biologic vaccines and drugs of interest for human health indications. The company was founded in 1979 and is headquartered in Jupiter, Florida.
Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.